Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)

NCT02298647 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-02-13

No results posted yet for this study

Summary

Development of a new MS-based biomarker for the ear-ly and sensitive diagnosis of GM1/GM2 from blood

Conditions

  • Hepato-splenomegaly
  • Dysostosis Multiplex
  • Seizures
  • Mental Retardation

Sponsors & Collaborators

  • CENTOGENE GmbH Rostock

    lead INDUSTRY

Principal Investigators

  • Peter Bauer, Prof. · Centogene GmbH

Eligibility

Min Age
2 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-20
Primary Completion
2021-02-28
Completion
2021-02-28

Countries

  • Egypt
  • Germany
  • India
  • Sri Lanka

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02298647 on ClinicalTrials.gov